Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
C 2.36 11.85% 0.25
RGLS closed up 11.85 percent on Monday, March 18, 2024, on 24 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Walk Strength 11.85%
Inside Day Range Contraction 11.85%
Wide Bands Range Expansion 11.85%
Upper Bollinger Band Touch Strength 11.85%
New 52 Week Closing High Bullish -3.48%
Pocket Pivot Bullish Swing Setup -3.48%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 11 hours ago
Upper Bollinger Band Resistance about 12 hours ago
Up 10% about 13 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Down 3% about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Hepatocellular Carcinoma Oligonucleotide Regulus Therapeutics RNA Nucleic Acids Alnylam Pharmaceuticals Atherosclerosis Hepatitis C Virus Infection Nucleotides

Is RGLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.79
52 Week Low 0.772
Average Volume 3,607,850
200-Day Moving Average 1.41
50-Day Moving Average 1.47
20-Day Moving Average 1.69
10-Day Moving Average 1.89
Average True Range 0.33
RSI (14) 70.33
ADX 32.35
+DI 40.33
-DI 11.09
Chandelier Exit (Long, 3 ATRs) 2.79
Chandelier Exit (Short, 3 ATRs) 2.32
Upper Bollinger Bands 2.46
Lower Bollinger Band 0.92
Percent B (%b) 0.94
BandWidth 90.76
MACD Line 0.22
MACD Signal Line 0.13
MACD Histogram 0.0908
Fundamentals Value
Market Cap 47.73 Million
Num Shares 20.2 Million
EPS -1.59
Price-to-Earnings (P/E) Ratio -1.48
Price-to-Sales 7.43
Price-to-Book 1.12
PEG Ratio -0.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.93
Resistance 3 (R3) 2.88 2.65 2.83
Resistance 2 (R2) 2.65 2.50 2.67 2.80
Resistance 1 (R1) 2.50 2.41 2.57 2.55 2.77
Pivot Point 2.27 2.27 2.30 2.29 2.27
Support 1 (S1) 2.12 2.12 2.20 2.17 1.95
Support 2 (S2) 1.89 2.03 1.91 1.92
Support 3 (S3) 1.74 1.89 1.89
Support 4 (S4) 1.79